Technical Analysis for REPL - Replimune Group, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 32.73 | -4.16% | -1.42 |
REPL closed down 4.16 percent on Wednesday, March 3, 2021, on 1.13 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Historical REPL trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 0.00% | |
200 DMA Support | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Oversold Stochastic | Weakness | -4.16% | |
Slingshot Bearish | Bearish Swing Setup | -7.59% | |
Narrow Range Bar | Range Contraction | -7.59% | |
NR7 | Range Contraction | -7.59% | |
Oversold Stochastic | Weakness | -7.59% | |
Oversold Stochastic | Weakness | -5.49% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Lower Bollinger Band Support | about 17 hours ago | |
200 DMA Support | about 17 hours ago | |
Down 5% | about 18 hours ago | |
Down 3% | about 18 hours ago | |
Down 2 % | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/13/2020
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatments Virotherapy Immunotherapy Product Experimental Cancer Treatments Oncolytic Virus Rp1 Transgene Sa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatments Virotherapy Immunotherapy Product Experimental Cancer Treatments Oncolytic Virus Rp1 Transgene Sa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 54.85 |
52 Week Low | 8.58 |
Average Volume | 432,747 |
200-Day Moving Average | 32.05 |
50-Day Moving Average | 39.74 |
20-Day Moving Average | 37.37 |
10-Day Moving Average | 35.38 |
Average True Range | 2.53 |
ADX | 25.8 |
+DI | 12.32 |
-DI | 32.25 |
Chandelier Exit (Long, 3 ATRs ) | 37.97 |
Chandelier Exit (Short, 3 ATRs ) | 39.57 |
Upper Bollinger Band | 43.00 |
Lower Bollinger Band | 31.74 |
Percent B (%b) | 0.09 |
BandWidth | 30.12 |
MACD Line | -1.87 |
MACD Signal Line | -1.58 |
MACD Histogram | -0.2986 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 36.35 | ||||
Resistance 3 (R3) | 36.50 | 35.45 | 35.74 | ||
Resistance 2 (R2) | 35.45 | 34.53 | 35.37 | 35.54 | |
Resistance 1 (R1) | 34.09 | 33.96 | 33.57 | 33.94 | 35.34 |
Pivot Point | 33.04 | 33.04 | 32.78 | 32.96 | 33.04 |
Support 1 (S1) | 31.68 | 32.12 | 31.16 | 31.53 | 30.12 |
Support 2 (S2) | 30.63 | 31.55 | 30.55 | 29.92 | |
Support 3 (S3) | 29.27 | 30.63 | 29.72 | ||
Support 4 (S4) | 29.12 |